A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

被引：0
|
作者：
Kenjiro Aogi
Hiroshi Sakai
Hirohisa Yoshizawa
Norikazu Masuda
Nobuyuki Katakami
Yasuhiro Yanagita
Kenichi Inoue
Masaru Kuranami
Mitsuhiro Mizutani
Noriyuki Masuda
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Breast Oncology
[2] Saitama Cancer Center,Department of Thoracic Oncology
[3] Niigata University Medical and Dental Hospital,Bioscience Medical Research Center
[4] National Hospital Organization Osaka National Hospital,Department of Surgery
[5] Institute of Biomedical Research and Innovation,Division of Integrated Oncology
[6] Gunma Cancer Center,Department of Breast Oncology
[7] Saitama Cancer Center,Department of Breast Oncology
[8] Kitasato University School of Medicine,Department of Surgery
[9] Aichi Cancer Center Aichi Hospital,Department of Breast Surgery
[10] Kitasato University School of Medicine,Department of Respiratory Medicine
来源：
Supportive Care in Cancer | 2012年 / 20卷
关键词：
Palonosetron; 5-HT; receptor antagonist; Antiemetic; Chemotherapy-induced nausea and vomiting; Highly emetogenic chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1507 / 1514
页数：7
相关论文
共 50 条
  • [1] A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy
    Aogi, Kenjiro
    Sakai, Hiroshi
    Yoshizawa, Hirohisa
    Masuda, Norikazu
    Katakami, Nobuyuki
    Yanagita, Yasuhiro
    Inoue, Kenichi
    Kuranami, Masaru
    Mizutani, Mitsuhiro
    Masuda, Noriyuki
    SUPPORTIVE CARE IN CANCER, 2012, 20 (07) : 1507 - 1514
  • [2] Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
    Sachin, Hingmire
    Nirmal, Raut
    SOUTH ASIAN JOURNAL OF CANCER, 2015, 4 (01) : 7 - 10
  • [3] Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
    Choi, Brian S.
    Borsaru, Gabriela P.
    Ballinari, Gianluca
    Voisin, Daniel
    Di Renzo, Nicola
    LEUKEMIA & LYMPHOMA, 2014, 55 (03) : 544 - 550
  • [4] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Ralph Boccia
    Steven Grunberg
    Edwin Franco-Gonzales
    Edward Rubenstein
    Daniel Voisin
    Supportive Care in Cancer, 2013, 21 : 1453 - 1460
  • [5] A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
    Aapro, M. S.
    Grunberg, S. M.
    Manikhas, G. M.
    Olivares, G.
    Suarez, T.
    Tjulandin, S. A.
    Bertoli, L. F.
    Yunus, F.
    Morrica, B.
    Lordick, F.
    Macciocchi, A.
    ANNALS OF ONCOLOGY, 2006, 17 (09) : 1441 - 1449
  • [6] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy
    Rapoport, Bernardo
    Schwartzberg, Lee
    Chasen, Martin
    Powers, Dan
    Arora, Sujata
    Navari, Rudolph
    Schnadig, Ian
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : 23 - 30
  • [7] Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)
    Hesketh, Paul J.
    Morrow, Gary
    Komorowski, Anna W.
    Ahmed, Raza
    Cox, David
    SUPPORTIVE CARE IN CANCER, 2012, 20 (10) : 2633 - 2637
  • [8] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Boccia, Ralph
    Grunberg, Steven
    Franco-Gonzales, Edwin
    Rubenstein, Edward
    Voisin, Daniel
    SUPPORTIVE CARE IN CANCER, 2013, 21 (05) : 1453 - 1460
  • [9] A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
    Gralla, R. J.
    Bosnjak, S. M.
    Hontsa, A.
    Balser, C.
    Rizzi, G.
    Rossi, G.
    Borroni, M. E.
    Jordan, K.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1333 - 1339
  • [10] Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
    Hisanori Shimizu
    Kenichi Suzuki
    Takeshi Uchikura
    Daiki Tsuji
    Takeharu Yamanaka
    Hironobu Hashimoto
    Koichi Goto
    Reiko Matsui
    Nobuhiko Seki
    Toshikazu Shimada
    Shunya Ikeda
    Naoki Ikegami
    Toshihiro Hama
    Nobuyuki Yamamoto
    Tadanori Sasaki
    Journal of Pharmaceutical Health Care and Sciences, 4 (1)
12345